This is the third competing continuation application for the Cancer Center Support Grant at Vanderbilt lngram Cancer Center (VICC). VICC is a matrix center within Vanderbilt University Medical Center (VUMC) that integrates the cancer-related expertise and resources of the Schools of Medicine, Nursing, Arts and Sciences, Engineering;Peabody School of Education and the fully integrated Veterans Administration Medical Center. Most facilities are located on one campus, which promotes interactions, sharing of resources, and collaborations. Established in 1993, VICC functions as an organizational unit with a supra-departmental status. VICC-specific authorities and responsibilities are: 1) to conduct, coordinate and integrate cancer-related activities of Vanderbilt University;2) to carry out, support and enhance cancer research throughout the University;3) to develop, manage, and provide cancer education programs;and 4) to coordinate and integrate the care of cancer patients at VUMC. The research objectives are accomplished through seven research programs, two of which evolved out of previous programs and are considered new since the previous application. The programs are: Host-Tumor Interactions, Signal Transduction and Cell Proliferation, Genome Maintenance (new), Gastrointestinal Cancer, Thoracic/Head &Neck Cancer (new), Breast Cancer, and Cancer Epidemiology, Prevention and Control. Thirteen shared resources are proposed, 11 previously supported and two new. There has been remarkable VICC growth and accomplishments over the past project period. VICC has been awarded 11 new multi-investigator and six new training grants. In addition, we successfully renewed all three NCI SPOREs as well as eight multi-investigator and 11 training grants. With these and many other NCI grants, we increased our NCI funding by 62%. Significant investments have been made in cancer drug discovery, personalized cancer medicine, cancer epidemiology prevention and control, genomics, proteomics, informatics, bioinformatics, diversity initiatives, and cancer health disparities. Increased VICC space and facilities, along with philanthropic and institutional funds, supported the recruitment of 66 new faculty, who join a dedicated team carrying out the VICC mission: to alleviate cancer death and suffering through pioneering research, innovative clinical trials, evidence-based patient-care, prevention, education, and community activities.

Public Health Relevance

The Vanderbilt-lngram Cancer Center Support Grant provides the infrastructure support to facilitate basic, clinical and population-based research relevant to our mission to alleviate cancer death and suffering through pioneering research, innovative patient care, evidence-based prevention, education and communication. Our vision is to be a preeminent cancer center in the Southeast and a recognized leader, nationally and globally in the effort to prevent and treat cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA068485-15
Application #
8141440
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-09-17
Project End
2015-08-31
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
15
Fiscal Year
2011
Total Cost
$5,898,751
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Biochemistry
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Paul, Pritha; Rellinger, Eric J; Qiao, Jingbo et al. (2017) Elevated TIMP-1 expression is associated with a prometastatic phenotype, disease relapse, and poor survival in neuroblastoma. Oncotarget 8:82609-82620
Stephenson, Jason R; Wang, Xiaohan; Perfitt, Tyler L et al. (2017) A Novel Human CAMK2A Mutation Disrupts Dendritic Morphology and Synaptic Transmission, and Causes ASD-Related Behaviors. J Neurosci 37:2216-2233
Bouziat, Romain; Hinterleitner, Reinhard; Brown, Judy J et al. (2017) Reovirus infection triggers inflammatory responses to dietary antigens and development of celiac disease. Science 356:44-50
Moyo, T K; Wilson, C S; Moore, D J et al. (2017) Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition. Oncogene 36:4653-4661
Vilgelm, Anna E; Cobb, Priscilla; Malikayil, Kiran et al. (2017) MDM2 Antagonists Counteract Drug-Induced DNA Damage. EBioMedicine 24:43-55
LePage, Daniel P; Metcalf, Jason A; Bordenstein, Sarah R et al. (2017) Prophage WO genes recapitulate and enhance Wolbachia-induced cytoplasmic incompatibility. Nature 543:243-247
Li, Jun; Smith, Jarrod A; Dawson, Eric S et al. (2017) Optimized Translocator Protein Ligand for Optical Molecular Imaging and Screening. Bioconjug Chem 28:1016-1023
Zhang, Juliet; Weinrich, Jarret A P; Russ, Jeffrey B et al. (2017) A Role for Dystonia-Associated Genes in Spinal GABAergic Interneuron Circuitry. Cell Rep 21:666-678
Aune, T M; Crooke 3rd, P S; Patrick, A E et al. (2017) Expression of long non-coding RNAs in autoimmunity and linkage to enhancer function and autoimmune disease risk genetic variants. J Autoimmun 81:99-109
Esbenshade, Adam J; Zhao, Zhiguo; Aftandilian, Catherine et al. (2017) Multisite external validation of a risk prediction model for the diagnosis of blood stream infections in febrile pediatric oncology patients without severe neutropenia. Cancer 123:3781-3790

Showing the most recent 10 out of 2332 publications